Aurinia Pharma director Tang buys $13.59m in shares

Published 05/08/2025, 22:36
Aurinia Pharma director Tang buys $13.59m in shares

Director Kevin Tang purchased 1,300,000 shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) between August 1 and August 5, 2025. The purchases were made at prices ranging from $10.12 to $11.68, for a total value of $13,590,000. The stock has shown remarkable momentum, delivering a 113% return over the past year. According to InvestingPro data, management’s share purchases align with the company’s strong performance, with the stock currently trading near its 52-week high of $11.48.

The transactions increased Tang’s indirect ownership to 11,329,500 shares. The shares are indirectly owned by Tang Capital Partners (WA:CPAP), LP and Tang Capital Partners International, LP, of which Kevin Tang is the sole manager. With a market capitalization of $1.54 billion and an "GREAT" Financial Health score from InvestingPro, Aurinia shows strong fundamentals. Discover 15 more exclusive ProTips and comprehensive analysis in the Pro Research Report, available with an InvestingPro subscription.

In other recent news, Aurinia Pharmaceuticals reported second-quarter earnings that exceeded analyst expectations, driven by robust sales of its lupus nephritis treatment, LUPKYNIS. The company posted adjusted earnings per share of $0.16, surpassing the analyst estimate of $0.14. Revenue for the quarter reached $70 million, exceeding the consensus estimate of $64.27 million and marking a 22% increase from the $57.2 million reported in the same period last year. Aurinia Pharmaceuticals also raised its full-year revenue guidance, indicating a positive outlook for continued growth. These developments reflect the company’s strong performance and market presence. No recent mergers or acquisitions have been reported. Additionally, there have been no recent analyst upgrades or downgrades for the company. Investors may find these updates noteworthy as they assess Aurinia Pharmaceuticals’ financial health and market trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.